All In Biotech

Drug Trial Radar · NCT05515770

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir

An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)

Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,200

Planned (sponsor's estimate)

Start

Sep 20, 2022

Primary completion

Oct 2025

Study completion Feb 2026

Sponsor

Lead sponsor
Evandro Chagas National Institute of Infectious DiseaseAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beatriz Grinsztejn; Thiago Torres; Valdilea Gonçalves; Brenda Hoagland
First posted
Aug 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical trials, additional research is needed to evaluate effectiveness in real world settings as well as to identify effective implementation strategies. The proposed implementation study will assess the safety and effectiveness of open label CAB LA PrEP when offered at public health facilities to cisgender men and transgender or gender non-binary individuals who have sex with persons assigned male at birth. The study will also evaluate two nested implementation strategies, an mHealth education and decision support tool and a WhatsApp injection appointment reminder. The study will also assess overall facilitators and barriers to integrating CAB LA into existing oral PrEP services.

Conditions

  • HIV Infections

Interventions

  • Cabotegravir InjectionDrug

    Long action cabotegravir injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incident HIV infectionTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ

    Rio de Janeiro, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.